EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EyePoint Pharmaceuticals, Inc.

DEXYCU® (dexamethasone intraocular suspension)

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg

Life at EyePoint Pharma

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

	Jun '14	Jun '15	Jun '16	Jun '17	Jun '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	3.47M -	26.57M 664.90%	1.62M 93.90%	7.54M 365.37%	2.96M 60.72%	20.36M 587.77%	34.44M 69.10%	36.94M 7.27%	41.40M 12.09%	46.02M 11.14%
cost of revenue	78K -					2.69M -	5.82M 116.75%	8.18M 40.40%	8.33M 1.82%	4.63M 44.37%
gross profit	3.40M -	26.57M 682.47%	1.62M 93.90%	7.54M 365.37%	2.96M 60.72%	17.68M 497.03%	28.61M 61.86%	28.76M 0.52%	33.08M 15.01%	41.39M 25.12%
selling and marketing expenses					1.51M -	29.77M 1,869.05%	25.29M 15.04%	27.50M 8.74%	25.51M 7.26%	11.69M 54.17%
general and administrative expenses	7.47M -	8.06M 7.87%	9.01M 11.88%	11.23M 24.65%	11.54M 2.76%	17.94M 55.38%	20.73M 15.54%	25.57M 23.40%	34.82M 36.14%	40.10M 15.18%
selling general and administrative expenses	7.47M -	8.06M 7.87%	9.01M 11.88%	11.23M 24.65%	13.06M 16.22%	47.71M 265.41%	46.02M 3.55%	53.08M 15.34%	60.32M 13.65%	50.69M 15.98%
research and development expenses	9.57M -	12.09M 26.27%	14.38M 18.97%	14.88M 3.47%	16.18M 8.72%	15.37M 5.01%	17.42M 13.38%	28.50M 63.57%	49.64M 74.18%	64.36M 29.65%
other expenses	7.26M -	3K 99.96%	13.98M 466,000%	8.31M 40.56%	14.84M 78.50%	2.46M 83.42%	2.46M 0%	2.46M 0%	2.05M 16.67%
cost and expenses	17.04M -	20.14M 18.21%	23.39M 16.13%	26.11M 11.63%	29.23M 11.95%	68.23M 133.37%	71.73M 5.13%	92.22M 28.56%	120.34M 30.50%	119.68M 0.55%
operating expenses	17.04M -	20.14M 18.21%	23.39M 16.13%	26.11M 11.63%	29.23M 11.95%	65.54M 124.18%	65.90M 0.56%	84.04M 27.52%	112.02M 33.29%	115.05M 2.71%
interest expense	1K -				720K -	6.18M 757.78%	7.26M 17.50%	5.50M 24.24%	3.19M 42.00%	1.25M 60.90%
ebitda	-12.64M -	6.42M 150.78%	-21.77M 439.11%	-18.58M 14.69%	-26.17M 40.90%	-44.35M 69.44%	-34.77M 21.59%	-52.52M 51.05%	-74.76M 42.33%	-73.20M 2.09%
operating income	-13.49M -	6.42M 147.60%	-21.77M 439.11%	-18.58M 14.69%	-26.27M 41.44%	-47.86M 82.16%	-37.29M 22.09%	-55.28M 48.23%	-78.94M 42.81%	-73.66M 6.68%
depreciation and amortization	917K -	882K 3.82%	908K 2.95%	815K 10.24%	1.15M 40.86%	3.51M 206.10%	2.52M 28.34%	2.75M 9.29%	4.18M 51.93%	464K 88.90%
total other income expenses net	78K -	3K 96.15%	72K 2,300%	91K 26.39%	-26.28M 28,976.92%	-8.93M 66.01%	-8.10M 9.27%	-3.14M 61.24%	-23.32M 642.31%	2.95M 112.65%
income before tax	-13.48M -	6.44M 147.78%	-21.70M 436.83%	-18.48M 14.82%	-53.17M 187.64%	-56.79M 6.81%	-45.39M 20.07%	-58.42M 28.69%	-102.25M 75.04%	-70.71M 30.85%
income tax expense	-130K -	96K 173.85%	-155K 261.46%	-815K 425.81%	-25.56M 3,035.95%	6.18M 124.16%	7.26M 17.50%	5.50M 24.24%	22.26M 304.84%	83K 99.63%
net income	-13.36M -	6.35M 147.53%	-21.55M 439.48%	-18.48M 14.21%	-53.17M 187.64%	-62.97M 18.43%	-52.65M 16.39%	-63.91M 21.39%	-124.51M 94.81%	-70.80M 43.14%
weighted average shs out	2.74M -	2.94M 7.05%	3.16M 7.64%	3.53M 11.77%	4.62M 30.79%	10.43M 125.65%	12.84M 23.06%	28.76M 124.04%	37.32M 29.76%	38.90M 4.25%
weighted average shs out dil	2.74M -	3.06M 11.44%	3.16M 3.40%	3.53M 11.77%	4.62M 30.79%	10.43M 125.65%	12.84M 23.06%	28.76M 124.04%	37.32M 29.76%	38.90M 4.25%
eps	-4.87 -	2.20 145.17%	-6.81 409.55%	-5.23 23.20%	-11.50 119.89%	-6.04 47.48%	-4.10 32.12%	-2.22 45.85%	-3.34 50.45%	-1.82 45.51%
epsdiluted	-4.87 -	2.10 143.12%	-6.81 424.29%	-5.23 23.20%	-11.50 119.89%	-6.04 47.48%	-4.10 32.12%	-2.22 45.85%	-3.34 50.45%	-1.82 45.51%

COM:EYEPOINTPHARMA

EyePoint Pharmaceuticals

Last Close

8.35

22/11 21:00

Market Cap

452.61M

Beta: -

Volume Today

1.10M

Avg: -

Preview